Abstract Library

#1790 Lanreotide Autogel/Depot (LAN) in Lung Neuroendocrine Tumours (NETs): The Randomized, Double-Blind, Placebo (PBO)-Controlled, International Phase 3 SPINET Study

Introduction: Treatment options for advanced lung NETs are limited. The phase 3 CLARINET study demonstrated antitumour efficacy of somatostatin analogue (SSA) LAN 120mg vs PBO for metastatic gastroenteropancreatic grade 1/2 (Ki-67<10%) NETs, but prospective data on SSAs in advanced lung NETs are lacking.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Reidy-Lagunes D, Kulke M, Wolin E, Singh S, Ferone D,

Keywords: Lung NETs, lanreotide,

#1719 Escalated Dose Somatostatin Analogues for Anti-Proliferative Effect in Gastroenteropancreatic Neuroendocrine Tumours (GEPNETS): A Systematic Review

Introduction: Somatostatin analogues (SSAs) are the cornerstone of systemic therapy for well-differentiated GEPNETs. Dose escalation of SSAs is often trialled in clinical practice, but small studies have yielded mixed results.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Chan D, Ferone D, Segelov E, Albertelli M, Singh S,

Keywords: Escalated dose, octreotide, lanreotide, SSA,

#1127 Zebrafish as a New In Vivo Model to Study Angiogenesis in Neuroendocrine Tumors (NET)

Introduction: Zebrafish is a powerful model to study human diseases, including cancer.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author: Vitale G

Authors: Gaudenzi G, Dicitore A, Cotelli F, Ferone D, Persani L,

Keywords: zebrafish, NET,